Regulatory Insider Filing: William Rastetter Insider Trade for 375,939 Shares of Fate Therapeutics Inc (NASDAQ:FATE)

November 28, 2016 - By Ellis Scott

Regulatory Insider Filing: William Rastetter Insider Trade for 375,939 Shares of Fate Therapeutics Inc (NASDAQ:FATE)

William Rastetter Insider Buy

As revealed in a public report which was filled with the D.C. based-SEC on November 28, 2016, William Rastetter an insider in Fate Therapeutics Inc and currently director, bought shares worth $999,998 US Dollars in the Pinksheet-listed company. He acquired 375,939 new shares, at average $2.7 per share. Today, he holds 577,632 shares or 1.76% of the Company’s market cap.

Fate Therapeutics Inc (NASDAQ:FATE) Ratings Coverage

Out of 6 analysts covering Fate Therapeutics (NASDAQ:FATE), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $8 is the highest target while $4 is the lowest. The $6.75 average target is 120.59% above today’s ($3.06) stock price. Fate Therapeutics has been the topic of 6 analyst reports since October 6, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Thursday, September 22 by TH Capital. The stock of Fate Therapeutics Inc (NASDAQ:FATE) earned “Outperform” rating by Raymond James on Tuesday, October 6. The stock of Fate Therapeutics Inc (NASDAQ:FATE) earned “Buy” rating by Roth Capital on Thursday, September 22. The stock of Fate Therapeutics Inc (NASDAQ:FATE) earned “Outperform” rating by Wedbush on Tuesday, November 8. BMO Capital Markets initiated the stock with “Outperform” rating in Tuesday, April 12 report. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo.

Insitutional Activity: The institutional sentiment increased to 0.82 in Q2 2016. Its up 0.26, from 0.56 in 2016Q1. The ratio increased, as 7 funds sold all Fate Therapeutics Inc shares owned while 11 reduced positions. 1 funds bought stakes while 9 increased positions. They now own 13.89 million shares or 11.32% less from 15.66 million shares in 2016Q1.

Lombard Odier Asset (Usa) accumulated 0.05% or 256,426 shares. Polaris Venture Mgmt V Ltd Llc owns 2.47M shares or 4.51% of their US portfolio. Jacobs Levy Equity Mngmt Inc holds 0.01% or 178,647 shares in its portfolio. Savings Bank Of America De reported 28,320 shares or 0% of all its holdings. Tocqueville Asset Lp last reported 22,000 shares in the company. Northern Tru accumulated 0% or 25,531 shares. Moreover, Bridgeway Mngmt has 0.01% invested in Fate Therapeutics Inc (NASDAQ:FATE) for 394,537 shares. Fmr Ltd Liability has 4.31M shares for 0% of their US portfolio. Board Of Trustees Of The Leland Stanford Junior University holds 0.07% or 291,067 shares in its portfolio. Vanguard Gp reported 657,573 shares or 0% of all its holdings. Blackrock Mgmt Ltd Llc last reported 4,327 shares in the company. Goldman Sachs Grp Inc reported 35,966 shares or 0% of all its holdings. Morgan Stanley holds 1,030 shares or 0% of its portfolio. Walleye Trading Ltd Liability Corporation holds 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 1,100 shares. Blackrock Advsrs Limited Liability Co has invested 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE).

About 253,745 shares traded hands or 33.84% up from the average. Fate Therapeutics Inc (NASDAQ:FATE) has risen 60.61% since April 25, 2016 and is uptrending. It has outperformed by 54.59% the S&P500.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $101.00 million. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. It currently has negative earnings. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

According to Zacks Investment Research, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.”

Analysts await Fate Therapeutics Inc (NASDAQ:FATE) to report earnings on March, 2. They expect $-0.29 earnings per share, down 11.54% or $0.03 from last year’s $-0.26 per share. After $-0.27 actual earnings per share reported by Fate Therapeutics Inc for the previous quarter, Wall Street now forecasts 7.41% negative EPS growth.

Another recent and important Fate Therapeutics Inc (NASDAQ:FATE) news was published by Medgadget.com which published an article titled: “Fate Therapeutics, Inc Clinical Trial Reviews and Clinical Trail Assessment ..” on September 14, 2016.

FATE Company Profile

Fate Therapeutics, Inc. (Fate Therapeutics), incorporated on April 27, 2007, is a clinical-stage biopharmaceutical company. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. The Firm programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. The Company’s adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>